MarketPulse — Real-Time Financial News & Market Analysis

Publicis Groupe acquires AdgeAI to integrate AI-powered predictive measurement with production capabilities, enabling real-time creative optimization and ROI improvement for advertisers.

Integer Holdings appoints independent directors James Flanagan and Aaron Kapito to board, signaling renewed growth focus with organic sales expected to return to market levels in 2026 and exceed them in 2027.

Sunrun installed 1.5 GWh of residential battery storage in 2025, capturing nearly half the U.S. market and operating 237,000 systems with 4.0 GWh capacity.

Cadrenal's 12-LOX inhibitor CAD-1005 shows preclinical promise for obesity and diabetes inflammation reduction, potentially complementing GLP-1 medications.

Incannex Healthcare receives FDA Fast Track Designation for IHL-42X sleep apnea treatment following positive Phase 2 results, plans optimized Phase 3 pathway.

Syra Health slashed net losses 76% to $896K in FY2025 as population health revenue surged 157%, though total revenue fell 9% due to reduced federal funding.

Monday.com stock down 46% YTD despite analyst $128 price target. Strong 2025 results offset by cautious 2026 guidance amid AI uncertainty and weak SMB demand.

Aveanna Healthcare acquires Family First Homecare, adding 27 pediatric care locations across seven states, closing Q2 2026.

U.S. Physical Therapy presents at Barclays healthcare conference, showcasing its 783-clinic network and diversified rehabilitation services across 44 states.

DJS Law Group files class action against $DRVN over alleged false statements regarding revenue overstatement and expense understatement in consolidated balance sheet.

Three digital-first businesses—Shopify, Remitly, and Chewy—offer attractive valuations amid growth stock repricing, with strong secular tailwinds and path to earnings expansion.

USA Rare Earth appoints former GlobalFoundries CEO Dr. Thomas Caulfield to board following $1.6B government funding and $1.5B private investment securing rare earth supply independence.

Seres Therapeutics swung to $5.7M 2025 profit from $125.8M loss, boosted by Nestlé VOWST sale, with $45.8M cash funding ops through Q3 2026.

Minerva Neurosciences CEO to present at Stifel CNS Forum March 18, 2026, as company initiates Phase 3 roluperidone trial for schizophrenia treatment.

Relmada Therapeutics to report Q4 2025 results March 19, 2026, following $160M oversubscribed fundraise and Leerink Partners conference presentation.

Indivior plans $400M convertible notes offering to refinance debt and fund buybacks, reflecting broader pharmaceutical sector refinancing trends.

$BUDA to report FY2025 earnings March 26, 2026, revealing UltraFresh juice category traction and financial health for investors tracking premium beverage innovation.

Johnson & Johnson submits EMA application for TECVAYLI monotherapy in relapsed/refractory multiple myeloma, citing 71% risk reduction in disease progression or death versus standard care.

Decent Holding executes 1-for-25 reverse split effective March 16, 2026, consolidating shares to maintain Nasdaq listing compliance amid trading pressures.

ProQR reported €92.4M cash, advanced lead program AX-0810 into Phase 1, and achieved $4.5M in Eli Lilly milestones, projecting runway into mid-2027.